A detailed history of Parkman Healthcare Partners LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 23,400 shares of NUVL stock, worth $2.13 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
23,400
Previous 42,888 45.44%
Holding current value
$2.13 Million
Previous $3.25 Million 26.44%
% of portfolio
0.34%
Previous 0.48%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.44 - $112.17 $1.31 Million - $2.19 Million
-19,488 Reduced 45.44%
23,400 $2.39 Million
Q2 2024

Aug 14, 2024

SELL
$62.76 - $81.61 $308,779 - $401,521
-4,920 Reduced 10.29%
42,888 $3.25 Million
Q1 2024

May 15, 2024

SELL
$72.35 - $88.99 $872,468 - $1.07 Million
-12,059 Reduced 20.14%
47,808 $3.59 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $2.54 Million - $4.81 Million
59,867 New
59,867 $4.41 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.92B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.